Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 6.71 -0.30% -0.02
MRSN closed down 0.3 percent on Tuesday, February 19, 2019, on 2.9 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical MRSN trend table...

Date Alert Name Type % Chg
Feb 19 Parabolic Rise Strength 0.00%
Feb 19 Upper Bollinger Band Walk Strength 0.00%
Feb 19 Weak + Overbought Other 0.00%
Feb 19 Wide Bands Range Expansion 0.00%
Feb 19 Overbought Stochastic Strength 0.00%
Feb 19 Upper Bollinger Band Touch Strength 0.00%
Feb 15 Upper Bollinger Band Walk Strength -0.30%
Feb 15 Weak + Overbought Other -0.30%
Feb 15 Wide Bands Range Expansion -0.30%
Feb 15 Overbought Stochastic Strength -0.30%

Older signals for MRSN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Medicine Biotechnology Cancer Immunology Chemotherapy Cancers Monoclonal Antibodies Antibody Drug Conjugates Adc
Is MRSN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.96
52 Week Low 2.845
Average Volume 132,351
200-Day Moving Average 10.7154
50-Day Moving Average 4.6838
20-Day Moving Average 5.068
10-Day Moving Average 5.903
Average True Range 0.4522
ADX 29.76
+DI 38.2179
-DI 10.9677
Chandelier Exit (Long, 3 ATRs ) 5.7684
Chandelier Exit (Short, 3 ATRs ) 4.2016
Upper Bollinger Band 7.0779
Lower Bollinger Band 3.0581
Percent B (%b) 0.91
BandWidth 79.317285
MACD Line 0.5664
MACD Signal Line 0.3482
MACD Histogram 0.2181
Fundamentals Value
Market Cap 152.4 Million
Num Shares 22.7 Million
EPS -16.23
Price-to-Earnings (P/E) Ratio -0.41
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.47
Resistance 3 (R3) 7.52 7.32 7.34
Resistance 2 (R2) 7.32 7.13 7.30 7.30
Resistance 1 (R1) 7.02 7.01 6.92 6.96 7.26
Pivot Point 6.82 6.82 6.77 6.79 6.82
Support 1 (S1) 6.51 6.63 6.41 6.46 6.16
Support 2 (S2) 6.31 6.51 6.29 6.12
Support 3 (S3) 6.01 6.31 6.08
Support 4 (S4) 5.95